Search research articles
Contact Us
Filters
Showing results (211-220 of 267) with videos related to
Page
of 27
Sort By:
The Journal of Pathology
|
June 8, 2010
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
Tarik Asselah, Ivan Bièche, Abdellah Mansouri, et al.
Hepatology (Baltimore, Md.)
|
April 12, 2018
Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort)
Dominique Wendum, Richard Layese, Nathalie Ganne-Carrié, et al.
Plos One
|
July 24, 2018
At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice
Roman Vangoitsenhoven, Miranda van der Ende, Katrien Corbeels, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis
Vlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
Journal of Hepatology
|
March 28, 2024
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Laurent Castera, Philippe Garteiser, Cédric Laouenan, et al.
Gastroenterology
|
February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Lancet (London, England)
|
August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Mazen Noureddin, Juan P Frias, Guy W Neff, et al.
Diabetes Care
|
December 23, 2020
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Scientific Reports
|
May 16, 2020
Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, et al.
Hepatology (Baltimore, Md.)
|
October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
Mohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 267) with videos related to
Sort By:
Page
of 27
The Journal of Pathology
|
June 8, 2010
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
Tarik Asselah, Ivan Bièche, Abdellah Mansouri, et al.
Hepatology (Baltimore, Md.)
|
April 12, 2018
Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort)
Dominique Wendum, Richard Layese, Nathalie Ganne-Carrié, et al.
Plos One
|
July 24, 2018
At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice
Roman Vangoitsenhoven, Miranda van der Ende, Katrien Corbeels, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis
Vlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
Journal of Hepatology
|
March 28, 2024
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Laurent Castera, Philippe Garteiser, Cédric Laouenan, et al.
Gastroenterology
|
February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Lancet (London, England)
|
August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Mazen Noureddin, Juan P Frias, Guy W Neff, et al.
Diabetes Care
|
December 23, 2020
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Scientific Reports
|
May 16, 2020
Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, et al.
Hepatology (Baltimore, Md.)
|
October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
Mohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Page
of 27